SolyPlus, a German-based biotech firm with a US presence via BioLuxus Labs, is pitching a patented hyaluronic acid (HA) granular solution for chronic wound care. The deck centers on a dramatic case study of a 2-year chronic diabetic wound healing in just 10 days using 5-7g of their HA granules. Their value proposition hinges on four pillars: non-toxicity, cost-effective production, ease of application, and rapid healing. Financially, the company projects a long pre-revenue runway, with sales for human use not commencing until 2029, eventually scaling to €45,000,000 by 2033. The team is led by…
Key takeaways
- The company utilizes patented HA-granular technology to treat chronic wounds, citing a specific case of an 8mm deep diabetic wound healing in 10 days (Slide 3).
- SolyPlus identifies four primary competitive advantages: body-own compounds, cost-effective production, simple application, and fast healing (Slide 5).
- The financial model predicts zero revenue from human use until 2029, requiring significant upfront investment (Slide 7).
- Total projected sales for human use are estimated to reach €125,000,000 cumulatively by 2033 (Slide 13).
- The leadership team includes a mix of biophysicists, biochemists, and economists, with experience from major firms like Bayer (Slide 9).
- Pre-clinical and clinical development costs are validated by third-party partners including Vivoscience GmbH and FGK (Slide 13).
- The company operates as SolyPlus GmbH in Germany and BioLuxus Labs, Inc. in Chicago, US (Slide 1).
- Licensing fees to SolyPlus are modeled at 12.5% of total sales, totaling €7,750,000 over the projected period (Slide 13).
SolyPlus Pitch Deck Analysis
The SolyPlus pitch deck, dated November 2024, presents a specialized medical technology focused on chronic wound care. The company, operating as SolyPlus GmbH in Germany and BioLuxus Labs in the US, aims to commercialize patented hyaluronic acid (HA) granules. The deck is structured to move from clinical proof-of-concept to competitive positioning, followed by a detailed 10-year financial roadmap. This teardown examines the seven provided slides to evaluate the strength of the investment case.
Slide 1: Title and Identity
The cover slide introduces SolyPlus GmbH and its US counterpart, BioLuxus Labs, Inc., based in Chicago. The tagline, "SOLID POLYMERS CREATING VALUE With passion for a healthier future," establishes the company's focus on polymer science within the healthcare sector. The inclusion of the BioLuxus logo and the specific mention of "Patented Hyalu Skin Pearls HIO" provides immediate clarity on the product's branding and intellectual property status.
Slide 3: Clinical Proof of Concept
Slide 3 is perhaps the most critical slide for a biotech startup: the evidence of efficacy. Titled "Anecdotal success with hyaluronic acid wound healer," it features graphic before-and-after photos of a diabetic foot wound. The data provided is specific: a 2-year chronic wound, 8mm in diameter and 5mm deep, healed after 10 days of treatment. The treatment protocol is detailed as 3 days of twice-daily application followed by 7 days of once-daily application, using a total of 5-7g of HA granules. This slide serves as a powerful visual hook for investors, demonstrating that the product works on difficult-to-treat, long-standing medical issues.
Slide 5: Competitive Landscape and Advantages
SolyPlus addresses the market competition by listing established players and their respective technologies. Competitors include MediWound (Bio-enzymes), Organogenesis/Tissue Regenix/Aplagraf (Living human cells), KCI/Acelity/3M (Negative Pressure Wound Therapy), and CINOGY System GmbH (Cold plasma). By contrasting these complex or mechanical treatments with their own, SolyPlus highlights four major advantages:
Usage of body-own compound without toxicity and immunicity. · Simple and cost-effective production. · Simple and fast application without the need of professional support. · Extreme fast healing success.
This positioning suggests a "low-tech" application for a "high-tech" material, which is often attractive due to lower barriers to adoption in clinical settings.
Slide 7: Financial Forecast Overview
This slide provides a visual representation of the company's 10-year financial trajectory. The chart shows a flat revenue line (Sales for human use) from 2024 to 2028, during which time the company is absorbing investment (represented by red bars). A significant inflection point occurs in 2029, where sales begin to climb sharply, reaching approximately €45,000,000 by 2033. The "Result" (net profit) follows a similar upward curve starting in 2029, indicating a high-margin business model once the commercialization phase begins.
Slide 9: Leadership and Expertise
The team slide features four key executives, emphasizing their professional credentials and previous affiliations. Dr. Joachim Bender (CEO) is a biochemist with a background at Bayer. Dr. Andreas Voigt (CSO) and Richard Andersen (COO) are both listed as inventors, suggesting that the core IP is held within the founding team. Ralph Böttcher (CFO) brings economic and tax consultancy expertise. The slide also displays logos for TheraKine and Capsolution, implying a track record of successful ventures or partnerships in the biotech space. This team composition covers the necessary bases of science, operations, and finance.
Slide 11: Contact Information
Slide 11 repeats the team photos and provides direct contact information, including email addresses and German phone numbers for all four executives. This level of transparency is standard but useful, reinforcing the accessibility of the leadership team for due diligence.
Slide 13: Detailed Financial Modeling
The final slide is a comprehensive spreadsheet detailing the 10-year plan. It breaks down sales, material costs (estimated at 15% of sales), and various operating costs. Notable details include:
Pre-clinical and clinical development: Budgeted at €4,000,000 between 2024 and 2026, validated by Vivoscience GmbH and FGK. · Production upscaling and registration: Managed between 2026 and 2028. · Marketing & Distribution: Budgeted at 10% of sales starting in 2027. · Licensing fees: A consistent 12.5% of total sales paid to SolyPlus.
The cumulative result by 2033 is projected at €67,375,000 , with a total investment requirement of €8,000,000 spread over the first five years. This slide provides the granular data necessary for an investor to evaluate the realism of the company's growth assumptions.
What Works in the SolyPlus Deck
The deck excels in its clinical evidence . The use of a specific, long-term chronic wound case study (Slide 3) provides immediate credibility to the technology's efficacy. Furthermore, the financial transparency on Slide 13 is exemplary. Many early-stage decks provide vague revenue projections; SolyPlus provides a line-by-line breakdown of costs, including third-party validation for their R&D estimates. This reduces the perceived risk regarding the "black box" of clinical trial costs. The team's pedigree , particularly the Bayer connection, also adds significant weight to their ability to navigate the complex life sciences landscape.
What is Missing from the SolyPlus Deck
Despite the strong financials and clinical proof, the deck has several omissions. There is no market size analysis (TAM/SAM/SOM). While the financial projections reach €45M, there is no context on what percentage of the global wound care market this represents. There is also no specific 'Ask' slide in the provided pages. While the investment needs are buried in the financial table (€8M total), a dedicated slide explaining the current round's terms, valuation, and use of proceeds is missing. Additionally, the deck lacks a regulatory roadmap . While registration costs are mentioned, a timeline for FDA or CE Mark approval is not explicitly mapped out, which is a critical milestone for medical devices.
Founder's Guide: What to Copy
Founders in the biotech or medtech space should emulate the validation strategy used on Slide 13. By citing specific firms (Vivoscience, FGK, Glatt) that have validated their cost estimates, SolyPlus moves the conversation from "we think it will cost this much" to "experts have confirmed it will cost this much." This is a powerful way to build trust with investors. Additionally, the competitive matrix on Slide 5 is well-executed; it doesn't just list names, but identifies the specific technological approach of each competitor, making the SolyPlus advantage (simplicity and cost) much clearer. Finally, the visual evidence on Slide 3 is a masterclass in showing rather than telling—if your product has a visible impact, that should be the centerpiece of your deck.
Frequently asked questions
- What is the core technology behind SolyPlus?
- SolyPlus utilizes patented hyaluronic acid (HA) granules. As described on Slide 3, these granules are applied to chronic wounds, such as diabetic ulcers. The technology leverages the body's own compounds to avoid toxicity and immunicity, promoting rapid tissue regeneration. The deck highlights a specific instance where a 2-year chronic wound was treated successfully with only 5-7 grams of the material over a 10-day period.
- What does the competitive landscape look like for SolyPlus?
- Slide 5 lists several major competitors and their technologies, including MediWound (bio-enzymes), Organogenesis (living human cells), KCI/3M (negative pressure therapy), and CINOGY System (cold plasma). SolyPlus positions itself against these by emphasizing that its HA granules are simpler to apply without professional support and are more cost-effective to produce than cellular or mechanical therapies.
- What are the projected financials for the company?
- The financials on Slide 13 show a long development cycle. The company expects no sales for human use from 2024 through 2028. Revenue is projected to start at €5,000,000 in 2029 and grow to €45,000,000 annually by 2033. The model forecasts a cumulative gross profit of €106,250,000 and a total investment requirement of €8,000,000 over the first five years.
- Who are the key members of the SolyPlus team?
- The team (Slide 9) is led by CEO Dr. Joachim Bender, a biochemist with experience at Bayer. He is joined by CSO Dr. Andreas Voigt (Biophysicist/Inventor), CFO Ralph Böttcher (Certified Economist), and COO Richard Andersen (Pharmacist/Inventor). The slide also mentions affiliations with TheraKine and Capsolution, suggesting a deep network in the pharmaceutical and biotech sectors.
- What are the main risks identified in the deck?
- While not explicitly listed as a 'risk' slide, the financials on Slide 13 reveal a significant 5-year pre-revenue period. The company must sustain operations and clinical trials from 2024 to 2028 without human-use sales. This requires consistent capital injections totaling €8,000,000 and successful navigation of clinical development and registration processes, which are validated by external partners but remain subject to regulatory hurdles.
